Headquarters: Tokyo, Japan
Founded: 2023 (University of Tokyo spin-out)
Focus: Brain-targeted nanopharmaceuticals for neurodegenerative diseases
Website: https://www.tni-u-tokyo.jp
Tokyo NeuroInnovation (TNI) is a University of Tokyo spin-out company developing next-generation brain-targeted drug delivery systems using proprietary nanoparticle technology. The company's core innovation addresses the most significant bottleneck in neurodegeneration drug development: delivering therapeutic compounds across the blood-brain barrier (BBB)[1].
The blood-brain barrier is a tightly regulated interface between the circulatory system and the central nervous system that prevents most molecules from entering the brain. While this protective function is essential for neural health, it has historically prevented otherwise promising therapeutics from reaching their targets in the brain. Tokyo NeuroInnovation has developed a family of brain-targeting nanoparticles that exploit endogenous receptor-mediated transcytosis pathways to achieve efficient and safe brain penetration[2].
The blood-brain barrier consists of a continuous layer of brain endothelial cells surrounded by pericytes and astrocyte end-feet. Tight junctions between endothelial cells restrict paracellular diffusion, while efflux transporters (P-glycoprotein, BCRP, MRP family members) actively pump lipophilic molecules back into the bloodstream. Together, these features restrict brain penetration to small molecules (<400 Da) that are not substrates for efflux transporters[3].
Tokyo NeuroInnovation's technology exploits receptor-mediated transcytosis (RMT), a natural mechanism used by essential molecules like transferrin, insulin, and LDL to cross the BBB[3:1]. By decorating nanoparticles with ligands for BBB receptors, the company enables transport across the barrier through vesicular trafficking pathways.
Key receptors exploited by TNI's platform:
TNI's nanoparticles are engineered from biocompatible polymers and surface-functionalized with brain-targeting ligands. The platform features:
Target: Delivery of PGC-1alpha activators to brain
Stage: Preclinical (formulation optimization)
Indication: Parkinson's disease (mitochondrial dysfunction targeting)
TN-401 encapsulates mitochondrial protective compounds in brain-targeted nanoparticles for enhanced CNS delivery. The targeting approach increases brain accumulation by 10-20 fold compared to free drug, enabling oral dosing with adequate brain exposure[6].
Target: Anti-tau antibody delivery
Stage: Preclinical (proof-of-concept)
Indication: Alzheimer's disease
Large molecules like monoclonal antibodies do not cross the BBB efficiently. TN-402 uses TNI's nanoparticle platform to deliver anti-tau antibodies across the barrier, potentially enabling antibody-based therapies for Alzheimer's disease to achieve therapeutic brain concentrations with manageable dosing regimens.
Tokyo NeuroInnovation offers:
TNI's platform intersects with multiple NeuroWiki mechanisms:
Tokyo NeuroInnovation. Company Profile - Brain-Targeted Nanopharmaceuticals. 2024. ↩︎
Batrakova EV, et al. Nanocarriers for brain drug delivery: strategies and challenges. Journal of Controlled Release. 2022. ↩︎
Tam JC, et al. Transferrin receptor-mediated transcytosis for brain delivery of therapeutics. Advanced Drug Delivery Reviews. 2021. ↩︎ ↩︎ ↩︎
Demeule M, et al. LRP-mediated transcytosis of nanoparticles for brain drug delivery. Molecular Therapy. 2021. ↩︎ ↩︎
Kreuter J, et al. Nanoparticle technology for drug delivery across the blood-brain barrier. European Journal of Pharmaceutics and Biopharmaceutics. 2023. ↩︎
Michaud-Levesque J, et al. Angiopep-conjugated nanoparticles for brain delivery. Bioconjugate Chemistry. 2022. ↩︎